eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
Rhea-AI Summary
eXoZymes (NASDAQ:EXOZ) reported results from a 100-liter pilot run producing N-trans-caffeoyltyramine (NCT): ~99% reaction conversion, 91% process recovery, 90% isolated yield, 535 grams isolated, and 99.6% pharma-grade purity. The run was executed by Cayman Chemical, demonstrating protocol transferability and improved reaction performance at larger scale. eXoZymes plans 2026 work to establish commercial supply chains, expand volumes, form strategic partnerships, and finalize technology-transfer packages for commercial manufacturing and formulation development.
Positive
- Reaction conversion approximately 99%
- Process recovery 91% and isolated yield 90% yielding 535 g of NCT
- Final product purity measured at 99.6% (pharma-grade)
- Successful external tech transfer to Cayman Chemical demonstrating operational robustness
Negative
- Commercial NCT supply chain and sustainable economics are still under development for 2026
- Scaling and efficiency improvements remain a stated near-term focus before large-scale commercialization
News Market Reaction – EXOZ
In the Jan 30 session, EXOZ gained 2.06%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 11 | NCT scale-up data | Positive | -0.7% | Announced 100× NCT production scale-up with >99% feedstock conversion under partner ops. |
| Nov 13 | Q3 2025 update | Neutral | -0.6% | Scheduled Q3 2025 webinar covering results, commercialization progress, hires, and milestones. |
| Nov 13 | Leadership changes | Neutral | -0.6% | Appointed co-founder as CSO and named new chief of staff to support scaling efforts. |
| Nov 10 | Earnings webinar plan | Neutral | +14.3% | Announced scheduling of Third Quarter 2025 update webinar with management Q&A for investors. |
| Oct 30 | Conference participation | Positive | +13.9% | CEO featured on AI in life sciences panel, highlighting exozyme platform and NCT positioning. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News flow has been mostly operational or corporate and price has usually moved in the same direction as the perceived tone, with one notable selloff on a positive NCT scale-up update.
Over the last few months, eXoZymes has focused on NCT and platform validation. On Oct 30, 2025, it highlighted its AI‑engineered exozymes and NCT at an AI life‑sciences conference, with a double‑digit positive move. Multiple Nov 13, 2025 updates covered Q3 results, strategy, and leadership changes, alongside a 10-Q showing operating losses and going‑concern language. On Dec 11, 2025, the company announced a 100× NCT scale‑up. Today’s pilot‑run data extends that narrative by adding full downstream performance metrics at 100‑liter scale and external tech transfer.
Key Terms
n-trans-caffeoyltyramine medical
pharma-grade medical
cell-free technical
biomanufacturing technical
n-trans-feruloyltyramine medical
in-vitro medical
preclinical medical
analytical characterization technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted scientific attention in exploratory studies related to lipid metabolism and energy utilization pathways.
The production was executed by an external partner under pilot-scale conditions using standardized protocols.
The pilot run achieved approximately
99% reaction conversion,90% isolated yield, and 535 grams of NCT at99.6% pharma-grade purity.Reaction performance was observed to improve at increased operating scale.
High-purity NCT now available for formulation development with commercial partners.
LOS ANGELES, CA / ACCESS Newswire / January 29, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - reported detailed downstream performance results from its recently completed 100-liter pilot production run of NCT. The results expand upon the previously announced 100× scale-up milestone and provide new data demonstrating manufacturability, material recovery, and product quality at commercially relevant scale.
Following completion of the pilot run and product isolation and purification, eXoZymes achieved approximately
"What makes this initial NCT pilot run profound is how counter to conventional experience these results are. In most biological systems, performance typically degrades as you scale - reactions become harder to control, yields drop, and variability increases. With our AI-enhanced enzymes - exozymes - we see the opposite trend." states co-founder of eXoZymes and VP of Development, Paul Opgenorth, PhD, and continues, "At very small laboratory scale, where cell-free reactions are usually developed and optimized, performance can actually be the weakest. It improves at the one-liter scale, and this scaled run at 100 liters further reinforces that the system benefits from operating at larger volumes. Seeing that behavior carry through to high recovery, isolated yield, and pharma-grade purity supports that exozymes represent a fundamentally different and more scalable biomanufacturing paradigm compared to existing approaches."
Using a NCT tech transfer package, the pilot production was executed by Cayman Chemical, which independently operated the cell-free reaction, downstream processing, isolation, and analytical confirmation. This marks the first time the exozyme-based biomanufacturing process has been run end-to-end by an external partner, demonstrating protocol transferability and operational robustness.
Team Lead of Biosolutions and R&D Services, Adrian Brückner, PhD, adds, "What stood out to me in this run was not just the impressive final performance numbers, but how straightforward and reliable the process proved to be under real operating conditions. The reaction was executed using a written, step-by-step protocol by an external team, and it performed exactly as intended. From a process perspective, that level of consistency - combined with high recovery, isolated yield, and purity at this scale - gives us confidence that the system is not only scalable, but operationally robust and well suited for continued manufacturing development. Importantly, this successful production of more than half a kilogram of pharma-grade purity NCT means that we're now ready to share formulation samples with relevant partners."
NCT has historically been difficult to supply at scale in purified form. Cell-based production methods commonly co-produce N-trans-feruloyltyramine (NFT), a closely related compound that has been reported in the scientific literature to exhibit different activity profiles from NCT in certain in-vitro and preclinical research settings, which can complicate interpretation when both compounds are present. Because of their close structural similarity, separating NFT from NCT is also costly. The exozyme-based process avoids these limitations, enabling direct production of highly pure NCT without co-production challenges.
Looking ahead, eXoZymes expects 2026 to focus on establishing a commercial NCT supply chain, expanding production volumes, forming strategic partnerships, and finalizing commercial technology-transfer packages. These efforts are expected to focus on improving manufacturing efficiency and scalability as eXoZymes and NCTx evaluate pathways toward sustainable commercial economics.
Formulation can be shipped to partners
With isolated high-purity NCT now produced at pilot scale, eXoZymes is actively engaging with partners interested in formulation development, product validation, and application-specific testing. The availability of high-purity material enables partners to move beyond feasibility studies and into hands-on evaluation under relevant conditions. Companies seeking to explore potential use cases, assess performance, or initiate collaborative development discussions are invited to contact eXoZymes to request samples and discuss next steps, right here:
https://exozymes.com/partners
About Cayman
Cayman Chemical helps make research possible by providing products and services to scientists worldwide. Cayman's collection includes high-quality biochemicals, assay kits, antibodies, and proteins, empowering researchers to understand the biological mechanisms of health and disease and develop new therapies. Cayman's scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, and fatty acids, and is highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, Cayman offers a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic.
Learn more at www.caymanchem.com
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce highly valuable natural products, via a commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, nutraceuticals and medicines.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more at exozymes.com
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes
SOURCE: eXoZymes
View the original press release on ACCESS Newswire